Remdesivir Effective, Well-Tolerated: Final Trial Report |
Journal Updates
eMediNexus Coverage from: 
Remdesivir Effective, Well-Tolerated: Final Trial Report

0 Read Comments                

A final report from the multinational ACTT-1 trial has confirmed that remdesivir is effective and well tolerated for reducing the time to recovery from COVID-19 infection.

The newly published ACTT-1 trial data revealed that the median time to recovery was 10 days for those on active therapy compared to 15 days for those on placebo. With a rate ratio of 1.29 (P less than .001), the recovery was about one third faster.In the final report, the significant advantage of remdesivir over placebo for the trial’s primary endpoint was strengthened by efficacy on several secondary endpoints. The benefits on secondary endpoints included a 50% greater odds ratio (OR, 1.5; 95% CI, 1.2-1.9) of significant clinical improvement by day 15 after adjusting for baseline severity, a shorter initial length of hospital stay (12 vs. 17 days) and fewer days on oxygen supplementation (13 vs. 21 days) for the subgroup on oxygen therapy at enrolment. The findings were published in the New England Journal of Medicine… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now